• This program is also available as a web-based self-study CME Enduring Material activity.
  Click Here for more information. (Available Soon)
  

Target Audience
Gastroenterologists, Internists, Hepatologists, Family Physicians, Clinical Pharmacists as well as related advanced-practice clinicians and Nurse specialists.

Seminar Agenda (Times May Vary)
This Continuing Education activity can be deployed in a variety of settings, but the core content will include the discussion of these topics. Each will be a 60-minute session.
• Discovery and natural history of the Primary Biliary Cholangitis, including the disease’s name change.
• Rate of Disease progression and why there is such variation.
• Prevalence and growth PBC in women and in men.
• The three prominent forms of PBC: How are they alike and how do they differ.
• The risk of liver failure and death increases as PBC progresses.
• Managing Pruritis in your PBC patients.
• Therapeutic agents available in the US for those with PBC and promising clinical trials
• The new and emerging therapies for Primary Biliary Cholangitis – Methods of action and potential benefits.
• PSC diagnosis, natural history, clinical course
• PSC treatment with UDCA and other treatments in development
• What are the major differences between PBC and PSC.
• Take-home lessons and Proactive next steps.

Learning Objectives
Those who actively participate in this activity will be able to:
1) Articulate the key elements in the progression of chronic cholestatic disease.
2) Explain how and why PBC patients are unaware of their disease status for so long.
3) Discuss the newest AASLD and EASL diagnostic guidelines and tests for PBC.
4) Prepare your practice to better screen patients and increase sensitivity to populations at risk.
5) Differentiate the three prominent forms of PBC: Typical, with AIH features and Preductopenic.
6) Address the clinical features that may present in the PBC patient.
7) Work with patients to better manage Cholestatic Pruritis and the current and future therapies.
8) Explore the current therapies for Primary Biliary Cholangitis – their effectiveness and potential risks.
9) Evaluate the potential of the newest  PBC therapies in late-stage development.
10)  Develop patient and staff education modules to recognize and then treat PBC in its earlier stages.

Registration Fees
There is no fee to attend this event but advance registration is requested to allow for event planning.

To Register
Click on a date and location below to register for a program

If online registration has closed you may still attend the event by registering as a walk-in the day of the program.

May 1 Costa Mesa, CA
Host: Vietnamese Physicians Association of Southern California
Venue: Maggiano’s Little Italy - Costa Mesa
Faculty: Brian Lee, MD - Hoag Digestive Health Institute
View the Course Flyer

Joint Provider Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

 Designation Statement
The University of Louisville School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 1.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1389. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Jointly Provided By


Disclosure of Ineligible Company Support
This activity has been supported by educational grants from CymaBay, Intercept, and Mirum.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Learner Consent Statement
Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.

CE Enduring Material Activity (Available Soon)
Welcome to On-line version of theImproving Diagnostic and Treatment Outcomes of Cholestatic Liver Disease. This Online CE Enduring Material will explore the general natural history of PBC and PSC and provide information on the latest drug therapies currently available as well as those under investigation.

You will have to register and create a user profile before you are able to view the material.
Once you have finished viewing the material you can either close the presentation window or select the CME Publisher Portal window at the top of the screen to continue with your post-test, evaluation, and generation of your CE certificate.

CLICK HERE to go to the enduring material activity landing webpage.